Treatment of @entity8 with a novel @entity669 kinase inhibitor. BACKGROUND: We have previously demonstrated an essential role for increased @entity12841 ( @entity12841 ) activity in mediating @entity8 and @entity2543 in @entity19 models of @entity8 ( @entity8 ). This study was designed to determine whether or not treatment with a newly developed inhibitor of @entity12841 @entity669 kinase activity ( @entity69485 ) would reduce renal and @entity253 in @entity19 @entity8 . METHODS: @entity69486 ( @entity69486 ) litters were treated with @entity69485 , an @entity12841 -specific @entity669 kinase inhibitor. Animals were treated by intraperitoneal injection beginning at postnatal day 7 and were treated until postnatal day 24 or 48. @entity69485 's effectiveness was measured by a reduction in the renal cystic index, an increased life span, and maintenance of normal renal function. RESULTS: Treatment of @entity69486 @entity19 with @entity69485 resulted in a marked reduction of collecting tubule (CT) @entity5409 , improved renal function, decreased @entity253 , and an increased life span. Untreated cystic animals died of @entity177 at postnatal day 24 (P-24) with a CT cystic index of 4.8, a maximal urine osmolarity of 361 mOsm, and moderate to severe @entity253 . Cystic animals treated with @entity69485 to postnatal day 48 (P-48) were alive and well with normal renal function, a reduced CT cystic index of 2.0 (P < 0.02), a threefold increased in maximum urinary concentrating ability (P < 0.01), and a significant decrease in biliary epithelial proliferation/ @entity82 (P < 0.01). CONCLUSION: This study demonstrates that @entity69485 has therapeutic effectiveness in improving histopathologic abnormalities and decreasing mortality in @entity19 @entity8 .

Treatment of @entity8 with a novel XXXX kinase inhibitor.

@entity8 :: ('MESH:D007674', 'Disease') :: ['polycystic kidney disease', 'renal cyst formation', 'ARPKD', 'autosomal recessive polycystic kidney disease'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity5409 :: ('MESH:D052177', 'Disease') :: ['cystic lesions'] @entity12841 :: ('13649(Tax:10090)', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity19 :: ('10090', 'Species') :: ['mice', 'murine'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure'] @entity2543 :: ('MESH:D017573', 'Disease') :: ['biliary epithelial hyperplasia'] @entity69486 :: ('83675(Tax:10090)', 'Gene') :: ['BPK', 'Balb/c-bpk/bpk'] @entity253 :: ('MESH:D001660', 'Disease') :: ['biliary abnormalities', 'biliary epithelial abnormalities'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine'] @entity69485 :: ('MESH:C413883', 'Chemical') :: ['EKI-785']
@entity669 :: (CHEBI:18186,Chemical) :: ['tyrosine']
